Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GE Aerospace (GE) vs Eli Lilly And Co (LLY) Price & Performance

GE AerospaceTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

GE Aerospace vs Eli Lilly And Co — how do they compare? GE Aerospace trades at $369.53 (market cap $381.89B), while Eli Lilly And Co trades at $1,209 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2.8× GE Aerospace's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.

GELLY
Market Cap
$381.89B$1.08T
Sector
IndustrialsHealth
52-Week High
$381.22$1.24K
52-Week Low
$265.93$639.43
Enterprise Value
$391.70B$1.13T
Dividend Yield
0.51%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Aerospace

GE Aerospace trades at $366.70, down 0.91% with bullish technical momentum and strong fundamental performance. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $2.02 exceeding expectations of $1.86. Revenue growth accelerated to $45.86 billion in 2025 with net income margin improving to 17.72%. Analyst consensus remains strongly positive with 24 buy ratings and a $414.11 price target, representing 13% upside potential.

The outlook remains favorable with strong aerospace demand, defense contract wins, and expanding order backlog driving growth. Key risks include elevated valuation multiples (P/E 43.4, P/S 7.68) and potential execution challenges amid heavy investment in MRO and manufacturing expansion. The company's improving cash flow generation and strategic positioning in commercial engines and defense sectors support continued upside potential.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GE Aerospace

General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.

Read more on GE

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY